FARN Stock Overview
Operates as a clinical stage drug discovery and development company.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Faron Pharmaceuticals Oy Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£2.50 |
| 52 Week High | UK£3.70 |
| 52 Week Low | UK£1.13 |
| Beta | -0.13 |
| 1 Month Change | 112.77% |
| 3 Month Change | 48.81% |
| 1 Year Change | -14.38% |
| 3 Year Change | -32.89% |
| 5 Year Change | 140.38% |
| Change since IPO | -9.91% |
Recent News & Updates
Shareholder Returns
| FARN | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 26.6% | -0.1% | 0.1% |
| 1Y | -14.4% | -21.6% | 6.4% |
Return vs Industry: FARN exceeded the UK Biotechs industry which returned -21.6% over the past year.
Return vs Market: FARN underperformed the UK Market which returned 6.4% over the past year.
Price Volatility
| FARN volatility | |
|---|---|
| FARN Average Weekly Movement | 16.6% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: FARN's share price has been volatile over the past 3 months.
Volatility Over Time: FARN's weekly volatility has increased from 11% to 17% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 34 | Juho Jalkanen | www.faron.com |
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab, which is in phase 2 clinical trial for indications of solid tumors; and in phase 1 clinical trial for indications of acute myeloid leukemia and myelodysplastic syndromes.
Faron Pharmaceuticals Oy Fundamentals Summary
| FARN fundamental statistics | |
|---|---|
| Market cap | UK£180.02m |
| Earnings (TTM) | -UK£26.48m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.8x
P/E RatioIs FARN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FARN income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €30.94m |
| Earnings | -€30.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 27, 2024
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -85.1% |
How did FARN perform over the long term?
See historical performance and comparison